Skip to main content
. 2018 Mar 31;17(1):1–10. doi: 10.12779/dnd.2018.17.1.1

Table 5. AEs during follow-up.

AEs ALC (n=30) Placebo (n=26)
Any AE 4 (13.3%) 2 (7.7%)
Dizziness 0 1
Cardiac arrest 1 0
Pyelonephritis 1 0
Fatty liver 1 0
Aggravation headache 1 0
Dyspesia 0 1

AE: adverse event, ALC: Acetyl-L-carnitine.

*Pearson correlation; 0.967 (p<0.001) between 1st and 2nd test.